Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @realJacobBell
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @realJacobBell
-
Prikvačeni tweet
Ever notice how biotechs like
$BIIB and$GILD are asked often about M&A, but$REGN not so much? I took a deep dive into why that is, and whether recent challenges to Regeneron's top-selling drug could change the company's dealmaking track record.https://www.biopharmadive.com/news/pharmacquired-regeneron-eylea-acquisitions-dealmaking/565087/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Jacob Bell proslijedio/la je TweetHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Biogen boosted as Mylan patent challenge fails
$BIIB$MYLhttps://www.biopharmadive.com/news/biogen-mylan-tecfidera-patent-decision/571784/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
RBC: "Among HCV products, Harvoni was generally in-line while Epclusa missed ($465M) despite strong Rx, perhaps suggesting continued price compression in the space. Yescarta continues to show very gradual growth ($122M) though we believe has become a lesser investor focus."
$GILDHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Jacob Bell proslijedio/la je Tweet
Impairment charge
$GILD took on Kite assets tied to treatment of indolent NHL, whereas in 2018 it was related to a specific asset, the anti-BCMA product KTE-585:pic.twitter.com/wH5IDnagHW
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Jacob Bell proslijedio/la je Tweet
$GILD CAR-T Yescarta sales flattening out.https://twitter.com/bradloncar/status/1224803781340209153 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$NBIX up more than 3% in afterhours trading on Q4 results. Co. reports total revenue of $244M for Q4 and $788M for FY19, up 86% and 75% year over year. Co. had cash/cash equivalents/marketable securities of $970M as of Dec. 31Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$CTLT Q2 earnings show its oral and specialty delivery segment was the only segment that didn't grow YoY. Co. says it was due to respiratory and ophthalmic volume declines related to delayed product approvals. Co. expects these delays will impact the next few quarters as well.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Jacob Bell proslijedio/la je TweetHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
It’s hard to find positive news, yet this week we confirmed in the Physical music video that Dua Lipa can pull off any color
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Jacob Bell proslijedio/la je Tweet
Take a gander at this


Thanks to painstaking investigative journalism by a sharp young reporter (@CNSmd@merrillcollege &@UofMaryland alum@alex_mann10), a bill that would keep court information public is working its way through the Maryland General Assembly#MDGA20.https://twitter.com/thejeffbarnes/status/1223368079239000064 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Jacob Bell proslijedio/la je Tweet
$BMY withdrawing EU application for approval of Opdivo/Yervoy combo in first-line lung cancer. The application was based on the CM-227 study results that the co. is using for its FDA application (PDUFA May 15) https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-withdraws-european-application-opdivo-niv …Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Jacob Bell proslijedio/la je Tweet
I caught up with
@Uber yesterday to learn why the company's risking its bottom line to increase public transit ridership in Boston.https://www.smartcitiesdive.com/news/uber-boston-app-update-public-transit/571454/ …Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
*the EDGAR search box. See! I told y’all today was bad
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Featuring interviews with
@jmaxlevin, Steven Paul of@KarunaPharma, Ted Dawson of@HopkinsMedicine, Paul Matteis of@Stifel and Phil Nadeau@CowenResearchPrikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.